BiotechTube

sonidegib

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Basal Cell Carcinoma

Conditions

Basal Cell Carcinoma

Trial Timeline

Mar 11, 2019 → Mar 14, 2025

NCT ID
NCT04066504

About sonidegib

sonidegib is a pre-clinical stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04066504. Target conditions include Basal Cell Carcinoma.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04066504Pre-clinicalCompleted

Competing Products

20 competing products in Basal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split DoseVerrica PharmaceuticalsPhase 2
44
Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
85
VismodegibSun PharmaceuticalPhase 2
52
Cemiplimab Injection [Libtayo]Sun PharmaceuticalPhase 2
52
Vismodegib + SonidegibSun PharmaceuticalPre-clinical
23
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
ABBV-8E12AbbViePre-clinical
23
Pembrolizumab + VismodegibMerckPhase 1/2
41
LDE225B + VehicleNovartisPhase 2/3
65
verteporfin PDTNovartisPhase 3
77
Vehicle + LDE225 0.25% + LDE225 0.75%NovartisPhase 2
52
LDE225NovartisPhase 2
52
LDE225 + PlaceboNovartisPhase 2
52
Buparlisib + SonidegibNovartisPhase 2
52
LDE225NovartisPre-clinical
23
LDE225 0.75% + VehicleNovartisPhase 2
52
VismodegibRochePre-clinical
23
ERIVEDGERochePhase 2
52
Placebo + VismodegibRochePhase 2
52
vismodegibRochePhase 2
52

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85